17 results
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex … , accumulation of excess body fat and the establishment and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like … and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex
424B5
c6994ln4
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
f4i 4rndtu
27 Sep 23
Prospectus supplement for primary offering
5:26pm
424B5
359rpwksrrhgz
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
4961vf90p5rw6mup
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
dna3w5
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
65b3h29mvy0q8gt63mr
15 Nov 18
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018
4:02pm
S-1/A
cr1j0 qklufzjbkcn
1 Jul 14
IPO registration (amended)
12:00am
- Prev
- 1
- Next